Browse Drug Recalls
3,394 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 3,394 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 3,394 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Jan 10, 2020 | ranitidine hydrochloride, USP ,150 mg tablets a) 14-count bottles ( NDC 430... | CGMP Deviations: Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts ... | Class II | PD-Rx Pharmaceuticals, Inc. |
| Jan 7, 2020 | Nizatidine Capsules, USP 150 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 037... | CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the ... | Class II | Mylan Pharmaceuticals Inc. |
| Jan 7, 2020 | Ranitidine Capsules 300 mg, 30 count bottles. Rx only, Manufactured by: Appco... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Appco Pharma LLC |
| Jan 7, 2020 | Nizatidine Capsules, USP 300 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 037... | CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the ... | Class II | Mylan Pharmaceuticals Inc. |
| Jan 7, 2020 | Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 300 mg, Rx Only, a) 14 co... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Preferred Pharmaceuticals, Inc |
| Jan 7, 2020 | Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottl... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Preferred Pharmaceuticals, Inc |
| Jan 7, 2020 | Ranitidine Capsules 150 mg, (a) 60 count bottles (NDC 62559-690-60) , (b) 500... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Appco Pharma LLC |
| Jan 6, 2020 | Ranitidine, 150 mg Tablets, a) 7 count, b) 14 count, c) 20 count, d) 30 count... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | H J Harkins Company Inc dba Pharma Pac |
| Dec 26, 2019 | Ranitidine 150 mg tablets, 24 count bottles, NDC 37808-196-01. | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | AAA Pharmaceutical, Inc. |
| Dec 26, 2019 | Ranitidine 150 mg tablets, 130 count bottles, NDC 37808-196-04. | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | AAA Pharmaceutical, Inc. |
| Dec 20, 2019 | Ranitidine Tablets, USP 150 mg , a). 4 count bottle (NDC 70934-017-04), b). 2... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Denton Pharma, Inc. |
| Dec 20, 2019 | Ranitidine Tablets, USP 300 mg a). 15-count bottles (NDC 70934-287-15), b). 9... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Denton Pharma, Inc. |
| Dec 17, 2019 | Glenmark Ranitidine Tablets USP 300 mg Rx Only 250 Tablets Manufactured by: G... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Glenmark Pharmaceuticals Inc., USA |
| Dec 17, 2019 | Glenmark Ranitidine Tablets USP 300 mg Rx Only 100 Tablets Manufactured by: G... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Glenmark Pharmaceuticals Inc., USA |
| Dec 17, 2019 | Glenmark Ranitidine Tablets USP 150 mg Rx Only 60 Tablets Manufactured by: Gl... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Glenmark Pharmaceuticals Inc., USA |
| Dec 17, 2019 | Glenmark Ranitidine Tablets USP 150 mg Rx Only 500 Tablets Manufactured by: G... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Glenmark Pharmaceuticals Inc., USA |
| Dec 17, 2019 | Glenmark Ranitidine Tablets USP 150 mg Rx Only 100 Tablets Manufactured by: G... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Glenmark Pharmaceuticals Inc., USA |
| Dec 17, 2019 | Glenmark Ranitidine Tablets USP 300 mg Rx Only 30 Tablets Manufactured by: Gl... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Glenmark Pharmaceuticals Inc., USA |
| Dec 13, 2019 | RANITIDINE TABLETS, USP 150mg, 10,000-count bag, Country of Origin: INDIA ND... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Granules India Limited |
| Dec 11, 2019 | Ranitidine 150 mg tablet Original Supplier's NDC 65162-0253-10 Remedy Repac... | CGMP Deviation; Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts a... | Class II | RemedyRepack Inc. |
| Dec 2, 2019 | Ranitidine Tablets, USP 150 mg, OTC, a.) 30 count bottle (NDC 68788-7078-03),... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | Preferred Pharmaceuticals, Inc |
| Nov 22, 2019 | Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).1... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Amneal Pharmaceuticals, Inc. |
| Nov 22, 2019 | Ranitidine Tablets, USP 300 mg, 250-count bottles, NDC 53746-254-02. | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Amneal Pharmaceuticals, Inc. |
| Nov 22, 2019 | Ranitidine Tablets, USP 150 mg a).60-count bottles (NDC 65162-253-06) , b).1... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Amneal Pharmaceuticals, Inc. |
| Nov 22, 2019 | Ranitidine Tablets, USP 150 mg, 1000-count bottles, NDC 53746-253-10. | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Amneal Pharmaceuticals, Inc. |
| Nov 22, 2019 | Ranitidine Syrup Oral Solution 15 mg/mL 6. fl. oz. (473 mL), NDC 65162-664-90. | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Amneal Pharmaceuticals, Inc. |
| Nov 20, 2019 | Ranitidine Tablets, USP, 150 mg, 100 Tablets (10 tablets x 10 blister card), ... | CGMP Deviations: Potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the ... | Class II | American Health Packaging |
| Nov 14, 2019 | AVKARE Ranitidine Tablets, USP 150 mg Rx Only Manufactured for: AvKARE, Inc. ... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | AVKARE Inc. |
| Nov 14, 2019 | AVKARE Ranitidine Tablets, USP 300 mg Rx Only NDC Manufactured for: AvKARE, I... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | AVKARE Inc. |
| Nov 14, 2019 | Yeast Arrest, Homeopathic Formula, Vaginal Support suppositories, packaged in... | cGMP violations | Class II | Wisconsin Pharmacal Company, LLC |
| Nov 13, 2019 | Ranitidine Oral Solution, USP, 150 mg/10 mL, [10 mL x 30 Unit Dose Cups per c... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API. | Class II | Precision Dose Inc. |
| Nov 8, 2019 | Calcarea Sulphurica 6X Tablets, 300-count bottle, 30g, Manufactured in India... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Silicea 6X Tablets, 300-count bottle, 30g, Manufactured in India exclusively ... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Natrum Sulphuricum 6X Tablets, 300-count bottle, 30g, Manufactured in India ... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Kali Phosphoricum 6X Tablets, 300-count bottle, 30g, Manufactured in India ex... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Natrum Muriaticum 6X Tablets, 300-count bottle, 30g, Manufactured in India ex... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | R2103, Active Ingredients: Berberis Aquifolium 3x; Borax 3; , Kreosotum 10X;... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Magnesia Phosphorica 6X Tablets, 300-count bottle, 30g, Manufactured in India... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Kali Muriaticum 6X Tablets, 300-count bottle, 30g, Manufactured in India excl... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Calcarea Fluorica 6X Tablets, 300-count bottle, 30g, Manufactured in India ex... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Ferrum Phosphoricum 6X Tablets, 300-count bottle, 30g, Manufactured in India ... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Kali Sulphuricum 6X Tablets, 300-count bottle, 30g, Manufactured in India exc... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Cell Salts Combination 6X Tablets, 300-count bottle, 30g, Manufactured in Ind... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Calcarea Phosphorica 6X Tablets, 300-count bottle, 30g, Manufactured in India... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | StellaLife VEGA Oral Gel Rinse (In equal parts of: Azadirachta Indica 1x, Cal... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Natrum Phosphoricum 6X Tablets, 300-count bottle, 30g, Manufactured in India ... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 8, 2019 | Pareira (Brava) 1X Tincture, 50 mL bottle, Washington Homeopathic Products, 2... | CGMP Deviations: products were not manufactured under current good manufacturing practices. | Class II | Washington Homeopathic Products, Inc. |
| Nov 6, 2019 | Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL (75 mg/5mL) 474 mL... | CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules ... | Class II | AuroMedics Pharma LLC |
| Nov 6, 2019 | Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by... | CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules ... | Class II | AuroMedics Pharma LLC |
| Nov 6, 2019 | Aurobindo Ranitidine Caspules 150 mg, 60-count bottle, Rx Only Distributed by... | CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules ... | Class II | AuroMedics Pharma LLC |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.